ArticleFrontiers in oncology2025
Ultrasound-guided radiofrequency ablation for the treatment of anaplastic thyroid cancer: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The shifting paradigm of programmed cell death ligand 1 (PD-L1) in anaplastic thyroid carcinoma: from pathology to clinical practice.Virchows Archiv : an international journal of pathology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anaplastic thyroid cancer (ATC) is a rare but highly aggressive tumor of the thyroid. Due to its rapid progression and resistance to radiotherapy, the prognosis of ATC is poor. Novel treatments have been increasingly applied in recent years, but the outcome of treatment is not satisfactory. Case presentation: We present a case of advanced ATC that cannot be surgically resected, who underwent ultrasound-guided radiofrequency ablation (RFA) combined with immunotherapy and targeted therapy for tumor shrinkage. The patient's symptoms, including neck pain, were significantly relieved, and the follow-up of this patient showed a satisfactory outcome with no associated complications. To the best of our knowledge, this is the first case of palliative treatment by RFA in a patient with advanced ATC. It exemplifies a new application and success of this classical approach in palliative treatment. Conclusion: This case indicates that RFA has a good therapeutic effect on elderly patients with advanced ATC. Such an approach will provide new ideas for the treatment of advanced ATC and warrants further study in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.